Dinah Weissmann

This inventor holds 6 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 10 EPO patents. Top assignees: Alcediag, Biocortech. Active years: 2008-2024.

USPTO Granted Patents = 6 (Patent Applications = 11)

% Patents Active = 83.3

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 15)

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Paris, FR (2008 - 2024)
Saint Mathieu de Tréviers, FR (2024)

Company Filing History:

Years Active: 2008-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084719 - RNA editing as biomarkers for mood disorders test (2024-09-10),

2. 11873531 - Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (2024-01-16),

3. 10851420 - Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (2020-12-01),

4. 10323283 - Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (2019-06-18),

5. 8771953 - Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platform (2014-07-08),

6. 7354918 - Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol and applications thereof (2008-04-08),

Title: Dinah Weissmann: Innovator in RNA Editing and Biomarkers

Introduction

Dinah Weissmann is a prominent inventor based in Paris, France. He has made significant contributions to the field of RNA editing and its applications in predicting mood disorders and other psychiatric conditions. With a total of 6 patents, Weissmann's work is at the forefront of biomedical innovation.

Latest Patents

Weissmann's latest patents include groundbreaking methods for utilizing RNA editing as biomarkers for mood disorders. One notable invention focuses on predicting the risk of psychiatric disorders through the analysis of A-to-I editing on PDE8A transcripts from body fluids such as blood, urine, or saliva. This method not only identifies patients at risk but also includes kits for practical implementation. Another significant patent involves the use of the editing profile of PDE8A pre-mRNA as a specific biomarker of ADARs activities in human tissues. This invention provides an in vitro method for predicting alterations in ADARs-catalyzed pre-mRNA editing, which can be crucial for diagnosing potential drug side effects and assessing therapeutic efficacy.

Career Highlights

Throughout his career, Dinah Weissmann has worked with notable companies such as Alcediag and Biocortech. His innovative approaches have positioned him as a key figure in the development of diagnostic tools and therapeutic strategies in the biomedical field.

Collaborations

Weissmann has collaborated with esteemed colleagues, including Laurent Vincent and Jean-Francois Pujol. These partnerships have further enhanced his research and contributions to the scientific community.

Conclusion

Dinah Weissmann's work in RNA editing and biomarkers represents a significant advancement in understanding and diagnosing mood disorders. His innovative patents and collaborations continue to influence the field of biomedical research.